ATE215379T1 - Antifungaleverfahren und mitteln - Google Patents

Antifungaleverfahren und mitteln

Info

Publication number
ATE215379T1
ATE215379T1 AT95908502T AT95908502T ATE215379T1 AT E215379 T1 ATE215379 T1 AT E215379T1 AT 95908502 T AT95908502 T AT 95908502T AT 95908502 T AT95908502 T AT 95908502T AT E215379 T1 ATE215379 T1 AT E215379T1
Authority
AT
Austria
Prior art keywords
agents
methods
antifungal
antifungal methods
fungal infection
Prior art date
Application number
AT95908502T
Other languages
English (en)
Inventor
Roger G Little
Edward Lim
Patrick J Scannon
Lewis H Lambert
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/209,762 external-priority patent/US5733872A/en
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of ATE215379T1 publication Critical patent/ATE215379T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95908502T 1994-01-14 1995-01-13 Antifungaleverfahren und mitteln ATE215379T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18322294A 1994-01-14 1994-01-14
US08/209,762 US5733872A (en) 1993-03-12 1994-03-11 Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US27354094A 1994-07-11 1994-07-11
PCT/US1994/010427 WO1995019372A1 (en) 1994-01-14 1994-09-15 Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
PCT/US1995/000498 WO1995019179A1 (en) 1994-01-14 1995-01-13 Anti-fungal methods and materials

Publications (1)

Publication Number Publication Date
ATE215379T1 true ATE215379T1 (de) 2002-04-15

Family

ID=27391654

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95908502T ATE215379T1 (de) 1994-01-14 1995-01-13 Antifungaleverfahren und mitteln

Country Status (11)

Country Link
US (1) US5627153A (de)
EP (1) EP0754049B1 (de)
JP (1) JPH09508357A (de)
CN (1) CN1112933C (de)
AT (1) ATE215379T1 (de)
AU (1) AU703211B2 (de)
CA (1) CA2181165C (de)
DE (1) DE69526216T2 (de)
HK (1) HK1014158A1 (de)
MX (1) MX9602570A (de)
WO (1) WO1995019179A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117974A (en) * 1991-10-02 2000-09-12 Peptor Limited Libraries of backbone-cyclized peptidomimetics
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
EP0824547B1 (de) * 1994-09-15 2003-12-10 XOMA Technology Ltd. Peptide gegen pilzen
AU727085B2 (en) * 1995-07-20 2000-11-30 Xoma Corporation Anti-fungal peptides
US5851802A (en) * 1996-03-22 1998-12-22 Xoma Corporation Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
CN1236320A (zh) * 1996-05-10 1999-11-24 爱克斯欧玛公司 杀菌的/增强通透性的蛋白质产物用于人脑膜炎球菌血症的治疗用途
US5945399A (en) * 1996-05-23 1999-08-31 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
USRE38984E1 (en) * 1996-09-12 2006-02-14 Merck & Co., Inc. Antifungal combination therapy
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US20020173464A1 (en) * 2000-12-01 2002-11-21 King George L. Modulation of pericyte proliferation
US6706688B2 (en) 2001-03-09 2004-03-16 Paula Sundstrom Methods for regulating bud-hypha transitions and cAMP levels by the adenylate cyclase-associated protein gene, CAP1
US7270975B2 (en) * 2001-03-09 2007-09-18 Trustees Of Dartmouth College Methods for regulating bud-hypha transitions and cAMP levels in Candida albicans
CN1950396A (zh) * 2004-02-24 2007-04-18 联邦科学技术研究组织 抗真菌肽
WO2006120496A1 (fr) * 2005-05-13 2006-11-16 Advanced Scientific Developements Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l’ eugenol, le thymol, le borneol, et le carvacrol
EP1741440A1 (de) 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
CN104745595B (zh) * 2015-03-27 2017-06-27 宁波大学 刺参bpi基因、编码蛋白及其克隆方法和重组刺参bpi基因工程菌构建方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126257A (en) * 1986-11-26 1992-06-30 Cornell Research Foundation Antimicrobial proteins, compositions containing same and uses thereof
US5087569A (en) * 1986-11-26 1992-02-11 Cornell Research Foundation, Inc. And The Rockefeller University Antimicrobial proteins, compositions containing same and uses thereof
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
AU9127591A (en) * 1990-12-03 1992-06-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
WO1993006228A1 (en) * 1991-09-26 1993-04-01 Incyte Pharmaceuticals, Inc. A new form of liposaccharide binding protein (lbp)
CA2276548C (en) * 1992-05-19 2001-07-31 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
EP0682524B1 (de) * 1993-02-02 2001-10-04 XOMA Technology Ltd. Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
DE69427582T2 (de) * 1993-03-12 2001-10-04 Xoma Technology Ltd Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten
DK0690721T3 (da) * 1993-03-12 1999-03-08 Xoma Corp Behandling af Mycobakterielle sygdomme ved indgivelse af baktericidt/permeabilitets-forøgende proteinprodukter
DE69412243T2 (de) * 1993-03-12 1999-03-25 Xoma Corp Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products

Also Published As

Publication number Publication date
CN1140999A (zh) 1997-01-22
DE69526216T2 (de) 2002-11-14
EP0754049A1 (de) 1997-01-22
MX9602570A (es) 1997-04-30
US5627153A (en) 1997-05-06
CA2181165A1 (en) 1995-07-20
WO1995019179A1 (en) 1995-07-20
CN1112933C (zh) 2003-07-02
DE69526216D1 (de) 2002-05-08
CA2181165C (en) 2007-06-05
AU1679795A (en) 1995-08-01
JPH09508357A (ja) 1997-08-26
EP0754049B1 (de) 2002-04-03
AU703211B2 (en) 1999-03-18
HK1014158A1 (en) 1999-09-24

Similar Documents

Publication Publication Date Title
ATE215379T1 (de) Antifungaleverfahren und mitteln
AU3909497A (en) Anti-chlamydial methods and materials
SG147274A1 (en) Prevention and treatment of amyloidogenic disease
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE257390T1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
DE69326776T2 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DE69530844D1 (de) Verfahren und substanzen gegen protozoen
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
ATE312909T1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
ZA951974B (en) Bradykinin antagonist peptides incorporating N-subsituted glycines
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ES2216630T3 (es) Metodos de tratar la hipertension dependiente de la sal.
ATE260559T1 (de) Sordarinderivate
EP1374887A4 (de) Neue mittel zur linderung von motorischen störungen
DE69813833D1 (de) 4-cyano-4-deformylsordarizin-derivate
DE69601154D1 (de) Zubereitungen für die Behandlung von Hepatitis C
DE69815355D1 (de) 4-cyano-4-deformylsordarinderivate
DE69910608D1 (de) Neue therapeutische verwendung von 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties